Beijing Scitop Bio-tech Co (300858) Q4 2024 earnings summary

Executive summary

• 2024 revenue reached ¥302.79 million, up 1.19% year-over-year, with net profit attributable to shareholders at ¥94.36 million, a 0.94% increase compared to 2023.

• Probiotic segment led growth, accounting for 76.5% of revenue, while compound food additives declined sharply.

• Cash dividend of ¥1.50 per 10 shares proposed, totaling ¥39.52 million, with no bonus shares or capital reserve transfer.

• R&D investment rose 6.24% to ¥36.33 million, representing 12% of revenue.

• Major production base projects advanced, with the microecological base completed and the food R&D base expected to finish in 2026.

Financial highlights

• Operating income: ¥302.79 million, up 1.19% year-over-year; net profit: ¥94.36 million, up 0.94%.

• Gross margin improved to 58.25% from 54.58% last year.

• Operating cash flow increased 32.49% to ¥142.11 million.

• Basic and diluted EPS: ¥0.36, up from ¥0.35 year-over-year.

• R&D expenses: ¥36.33 million, up 6.24% year-over-year.

Outlook and guidance

• 2025 focus on expanding probiotic and microecological product lines, accelerating domestic substitution for imported strains.

• Continued investment in R&D and production capacity, with new facilities to enhance efficiency and product innovation.

• Plans to deepen B2B and B2C market penetration, especially in probiotics and functional foods.